Jul 14 2008, 8:26 AM EST
News source: Business Wire
Laboratory Corporation of America(R) Holdings (LabCorp(R))
(NYSE:LH) is now offering ColoSure(TM), among the most sensitive,
in-guideline non-invasive colorectal cancer screening methods
available. ColoSure is in guidelines for assessing the presence of any
stage of colorectal cancer in asymptomatic average risk patients who
are unwilling or unable to undergo a more invasive exam (such as
colonoscopy, computed tomographic colonography, double contrast barium
enema, and flexible sigmoidoscopy). The assay is performed on a
complete bowel movement with a simple collection process, making it a
convenient and useful screening option. LabCorp's method examines DNA
in exfoliated colon cells for cancer-associated aberrant methylation
of the vimentin gene. ColoSure is a single marker laboratory
developed, stool based DNA test with a sensitivity range of 72-77% and
a specificity range of 83-94% in average risk individuals. The
ColoSure assay can be used as a part of a comprehensive, ongoing
colorectal cancer-screening program. Current guidelines emphasize
routine screening beginning at age 50.
"LabCorp is pleased to offer ColoSure to enhance the potential of
detecting and treating colorectal cancer in its early or localized
stage, when the likelihood of survival is greatest," said Myla P.
Lai-Goldman, M.D., Executive Vice President, and Chief Medical Officer
of LabCorp. "ColoSure is a significant addition to LabCorp's family of
advanced molecular tests, to aid in the detection, diagnosis,
prognosis, therapy selection, and surveillance of colorectal cancer."
It has been estimated that for the year 2008, 148,810 men and
women will be newly diagnosed with colorectal cancer. It has been
further estimated that 49,960 will die from the disease in 2008.
Colorectal cancer is the third most common cancer among women and men.
If colorectal cancer is diagnosed and treated at the localized stage,
the 5-year survival rate is 90%; unfortunately, only 39% of all cases
are found at the localized stage. Most colorectal cancers are detected
at the regional or distant stage when the 5-year survival rates are
68% and 10% respectively.
About LabCorp(R)
Laboratory Corporation of America(R) Holdings, a S&P 500 company,
is a pioneer in commercializing new diagnostic technologies and the
first in its industry to embrace genomic testing. With annual revenues
of $4.1 billion in 2007, over 26,000 employees nationwide, and more
than 220,000 clients, LabCorp offers clinical assays ranging from
routine blood analyses to HIV and genomic testing. LabCorp combines
its expertise in innovative clinical testing technology with its
Centers of Excellence: The Center for Molecular Biology and Pathology,
National Genetics Institute, Inc., ViroMed Laboratories, Inc., The
Center for Esoteric Testing, DIANON Systems, Inc., US LABS, and
Esoterix and its Colorado Coagulation, Endocrine Sciences, and
Cytometry Associates laboratories. LabCorp conducts clinical trial
testing through its Esoterix Clinical Trials Services division.
LabCorp clients include physicians, government agencies, managed care
organizations, hospitals, clinical labs, and pharmaceutical companies.
To learn more about our organization, visit our Web site at:
www.labcorp.com.
Each of the above forward-looking statements is subject to change
based on various important factors, including without limitation,
competitive actions in the marketplace and adverse actions of
governmental and other third-party payors. Actual results could differ
materially from those suggested by these forward-looking statements.
Further information on potential factors that could affect LabCorp's
financial results is included in the Company's Form 10-K for the year
ended December 31, 2007, and subsequent SEC filings.
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All